Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in ...

Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor ...

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding ...

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS’’ or the 'Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a ...

NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. Interim ...

ASH Presentation Details: Title ... molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate ...

CNAP displays verified caller names from telecom databases, boosting trust and authenticity beyond regular number-based ...

Just Transition Northwest Indiana has launched its “30 Days of Accountability” campaign, which encourages residents to express concerns.

If you’ve ever wished you could catch a stock’s move before it takes off, veteran trader Thomas Wood’s MQ Momentum Indicator might be what you’ve been ...

The first two meetings of HHS Secretary Robert F. Kennedy Jr.’s remade CDC vaccine advisory panel were marked by technical ...